Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics (APGE)
NASDAQ:APGE
Total Valuation
Apogee Therapeutics has a market cap or net worth of $2.37B. The enterprise value is ―.
Market Cap$2.37B
Enterprise Value―
Share Statistics
Apogee Therapeutics has 46,047,417 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,047,417
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Apogee Therapeutics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)0.00
Return on Assets (ROA)0.00
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee0.00
Profits Per Employee-929.32K
Employee Count196
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Apogee Therapeutics is 0.00. Apogee Therapeutics’s PEG ratio is 0.56.
PE Ratio0.00
PS Ratio0.00
PB Ratio2.15
Price to Fair Value3.49
Price to FCF-13.72
Price to Operating Cash Flow-12.81
PEG Ratio0.56
Income Statement
In the last 12 months, Apogee Therapeutics had revenue of 0.00 and earned 0.00 in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income-216.87M
Pretax Income-18.00K
Net Income0.00
EBITDA-216.87M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -171.17M and capital expenditures -1.15M, giving a free cash flow of -172.33M billion.
Operating Cash Flow-171.17M
Free Cash Flow-172.33M
Free Cash Flow per Share-3.74
Dividends & Yields
Apogee Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.65
52-Week Price Change-19.26%
50-Day Moving Average36.96
200-Day Moving Average44.43
Relative Strength Index (RSI)61.02
Average Volume (3m)703.49K
Important Dates
Apogee Therapeutics upcoming earnings date is Sep 1, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend Date―
Financial Position
Apogee Therapeutics as a current ratio of 18.55, with Debt / Equity ratio of 1.16%
Current Ratio18.55
Quick Ratio18.55
Debt to Market Cap<0.01
Net Debt to EBITDA0.60
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Apogee Therapeutics has paid -18.00K in taxes.
Income Tax-18.00K
Effective Tax Rate1.00
Enterprise Valuation
Apogee Therapeutics EV to EBITDA ratio is -10.93, with an EV/FCF ratio of -13.75.
EV to Sales0.00
EV to EBITDA-10.93
EV to Free Cash Flow-13.75
EV to Operating Cash Flow-13.85
Balance Sheet
Apogee Therapeutics has $520.65M in cash and marketable securities with $11.83M in debt, giving a net cash position of -$508.82M billion.
Cash & Marketable Securities$520.65M
Total Debt$11.83M
Net Cash-$508.82M
Net Cash Per Share-$11.05
Tangible Book Value Per Share$12.99
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Apogee Therapeutics is $93.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$93.63
Price Target Upside134.96% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-94.92%